

Ministry of Health

Ministère de la Santé

Office of Chief Medical Officer of Health, Public Health Bureau du médecin hygiéniste en chef, santé publique

Box 12

Boîte à lettres 12 Toronto ON M7A 1N3

Toronto ON M7A 1N3
Tel.: 416 212-3831
Fax: 416 325-8412

Tél.: 416 212-3831 **Téléc.**: 416 325-8412

May 20, 2022

SECTION 77.6 HEALTH PROTECTION AND PROMOTION ACT CHIEF MEDICAL OFFICER OF HEALTH ORDER

(Order to Public Hospitals to provide information relating to severe acute hepatitis of unknown origin among children)

ONTARIO MINISTRY OF HEALTH

ORDER OF THE CHIEF MEDICAL OFFICER OF HEALTH UNDER SECTION 77.6 OF THE HEALTH PROTECTION AND PROMOTION ACT.

R.S.O. 1990, c. H.2 (The Act)

WHEREAS under section 77.6 of the Act, the Chief Medical Officer of Health, where he is of the opinion that there exists an immediate and serious risk to the health of persons anywhere in Ontario, may issue an order directing any health information custodian, as defined in the *Personal Health Information Protection Act*, 2004 to provide to the Chief Medical Officer of Health or his or her delegate with any information provided in the order;

AND WHEREAS, under section 77.6(2), the Chief Medical Officer of Health is of the opinion, based on reasonable and probable grounds, that the information is necessary to investigate, eliminate or reduce the immediate and serious risk to the health of persons in Ontario presented by severe acute hepatitis of unknown origin among children;

AND WHEREAS, under section 77.6(3), the information requested in this order is to be used or disclosed only to investigate, eliminate, or reduce the risk and for no other purpose;

AND WHEREAS, under section 77.6(1), the Chief Medical Officer of Health may require health information custodians named in the order to disclose information, including personal health information, to a delegate;

AND HAVING REGARD TO severe acute hepatitis of unknown origin in children observed internationally as follows: Since October 2021, there have been, as of the date of this Order, at least 348 probable cases of acute hepatitis of unknown origin reported among children aged one month up to 16 years of age in 21 countries.

These cases are negative for hepatitis viruses A, B, C, D and E and have aspartate transaminase (AST) or alanine transaminase (ALT) levels over 500 U/L. The aetiology is considered unknown and active investigation continues; however, SARS-CoV-2 and adenovirus have been identified in some cases.

AND HAVING REGARD TO some cases having required transfers to specialist children's liver units, some having required liver transplantation, and there being at least one death reported as a result of infection.

THE CHIEF MEDICAL OFFICER OF HEALTH THEREFORE ORDERS pursuant to the provisions of section 77.6 of the Act that:

1. Every person or entity who operates a hospital within the meaning of the *Public Hospitals Act* ("Public Hospital"), any institution, building or other premises or place that is established for the purposes of the treatment of patients and that is approved under the *Public Hospitals Act* as a Public Hospital, must provide to the Chief Medical Officer of Health's delegate, the Ontario Agency for Health Protection and Promotion ("Public Health Ontario"), the information as outlined in Appendix B ("Case Report Form") respecting any cases of severe acute hepatitis of unknown origin among patients who are children ("Patients") and who meet the probable case definition in Appendix A (the "Information"). The Public Hospital must make best efforts to obtain the information from the parent or guardian (or child, where applicable) noted in sections 7 to 11 of the Case Report Form (Appendix B).

- 2. Every Public Hospital must disclose the Information to Public Health Ontario within one (1) business day after the Public Hospital learns that it has a Patient who meets the probable case definition in Appendix A.
- 3. Every Public Hospital must disclose the Information to Public Health Ontario. If a Public Hospital has a Patient that meets the probable case definition in Appendix A, the Public Hospital must contact Public Health Ontario at 647 260-7619 and provide the name and contact information for a representative of the Public Hospital that can be contacted by Public Health Ontario to report the information in the Case Report Form. Outside of business hours, a Public Hospital representative can call the above telephone number and leave a message, absent of personal health information.

This Order takes effect immediately and shall remain in force until revoked.

Dated at Toronto this 20 day of May, 2022

Dr. Kieran Moore

to for

Chief Medical Officer of Health

For more information on acute hepatitis and communications released by the Office of the Chief Medical Officer of Health, please visit https://www.health.gov.on.ca/en/pro/programs/publichealth/acute_hepatitis/de

fault.aspx.

APPENDIX A

CASE DEFINITIONS for severe acute hepatitis of unknown origin in children.

Confirmed case

• N/A at present.

Probable case

• A person who is 16 years and younger presenting with clinical evidence¹ of severe acute hepatitis since October 2021 and requiring hospitalization,

AND

• With elevated serum transaminase >500 IU/L (AST or ALT) or INR>2.0,

AND

• Excluding hepatitis caused or attributed to a hepatitis virus (A, B, C, D, E²) or a known or expected presentation of a drug or medication; a genetic, congenital, or metabolic condition; an oncologic, vascular, or ischemia related condition; or an acute worsening of chronic hepatitis.

¹ Clinical evidence of hepatitis may include jaundice, dark urine, pale stools, or non-specific symptoms (e.g., nausea, vomiting, diarrhea, abdominal pain).

² If hepatitis D or E serology results are pending or test was not done, but other criteria met, these can be reported as probable cases.

APPENDIX B

This case report form will require information from both the clinical team and the parent/guardian of the case (or the case themselves if they are an adult).

Date reported to PHAC (dd/mm/yyyy):		Initial report Updated report	
Section 1: Reporte	er details		
Public health auth	ority		
Name:		Title:	
Cell phone:		Email address:	
Province or Territory			
Clinician			
Name:		Title:	
Cell phone:		Email address:	
Organization:		Date of interview (dd/mm/yyyy):	

PART A: CLINICAL INFORMATION

Section 2: Case in	nformation			
First name:		Last name:		
Date of birth (dd/mm/yyyy):		Personal health identifier:		
Sex	Female □ Male □ Other □	Address during the 5 months prior to diagnosis Specify if there was another address during the period		
Section 3: Currer	nt case status			
Alive, recovered and discharged				
Alive, discharged	and recovering			
Alive, in hospital				
Alive, in intensive	care (ICU/CCU)			
Deceased				
Unknown				
More information:				
Name of hospital where diagnosisof acute hepatitis was made: Unknown 🗆				

			Hospital
	Yes□	Name of hospital	Links and D
Was liver transplant	No □	and date of liver	Unknown □
required?	Unknown	transplant if applicable:	Date
		, ,	Unknown □

Section 4: Presenting illness of case

Please provide a summary of the symptoms and signs of the presenting illness (including prodromal symptoms) and dates of onset if known:

Symptom	Symptom present	Symptom onset date (dd/mm/yyyy)
Jaundice	Yes□ No □	/ /
Nausea	Yes□ No □	/ /
Abdominal pain/ cramping	Yes□ No □	/ /
Diarrhea	Yes□ No □	/ /
Bloody stool	Yes□ No □	/ /
Pale stool	Yes□ No □	/ /
Dark urine	Yes□ No □	/ /
Rash	Yes□ No □	/ /
Vomiting	Yes□ No □	/ /
Respiratory Symptoms – shortness of breath, cough	Yes□ No □	/ /
Upper Respiratory Symptoms – runny nose, congestion, sore throat	Yes□ No □	/ /

Section 4: Presenting illness of case Please provide a summary of the symptoms and signs of the presenting illness (including prodromal symptoms) and dates of onset if known: Symptom present Symptom onset date Symptom (dd/mm/yyyy) Yes□ No□ / / Fever Malaise/tiredness Yes□ No□ / Yes□ No□ Conjunctivitis Other (please specify Yes□ No□ /

below):

Please provide clinical contact details of this presentation:				
Clinical contact	Clinical contacts during this presentation	Admission date – Discharge date (dd/mm/yyyy)		
Visited Family doctor or pediatrician	Yes□ No□			
Visited ER	Yes□ No□			
Admission to hospital (for at least 1 night)	Yes□ No□			
ICU/CCU admission	Yes□ No□			

NOTE: Please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed.

Laboratory marker	Result	Not tested	Pending	Date sample collected
Highest ALT				/ /
Highest AST				/ /
Highest Bilirubin				/ /
Highest INR				/ /
Highest Ferritin				/ /

Section 5: Laboratory results / Toxicology / Investigations

Infectious diseases	Detected	Not detected	Not tested	Pending	Date sample collected (dd/mm/yyyy)
CMV PCR in blood (indicate viral load if available)					/ /
EBV PCR in blood (indicate viral load if available)					/ /

Infectious diseases	Detected	Not detected	Not tested	Pending	Date sample collected (dd/mm/yyyy)
Enterovirus PCR in blood (indicate viral load if available					/ /
HSV – 1 PCR in blood (indicate viral load if available)					/ /
HSV – 2 PCR in blood (indicate viral load if available)					/ /
HAV: PCR in blood if done, or stool (please specify)					/ /
HAV: IgG					/ /
HAV: IgM					/ /
HBV (HBsAg)					/ /
HBV DNA					/ /
Hepatitis B antibody tests (please specify)					/ /
HCV (Ab)					/ /

Infectious diseases	Detected	Not detected	Not tested	Pending	Date sample collected (dd/mm/yyyy)
HCV RNA					/ /
HEV: IgM					/ /
HEV: IgG					/ /
HEV PCR in blood (or stool)- please specify					/ /
Adenovirus – stool sample					/ /
Adenovirus – respiratory sample					/ /
Adenovirus – blood sample (indicate viral load)					/ /
Adenovirus – other sample					/ /
Adenovirus genotyping (indicate sample used)					/ /
SARS-CoV-2 PCR – respiratory sample					/ /
SARS-CoV-2 anti-spike and/or anti-N antibody					/ /

Infectious diseases	Detected	Not detected	Not tested	Pending	Date sample collected (dd/mm/yyyy)
RSV PCR – respiratory sample					/ /
Influenza PCR – respiratory sample					/ /
Enterovirus PCR – respiratory sample					/ /
Varicella PCR in blood					/ /
Parvovirus B19 IgM or IgG or PCR, please indicate					/ /
EBV serology (IgG and IgM)					/ /
CMV serology (IgG and IgM)					/ /
Stool PCR for norovirus and/or enterovirus (select those included if not all available)					/ /
Other (please specify):					/ /

Toxicology	Detected	Not detected	Not tested	Pending	Date sample collected (dd/mm/yyyy)
Heavy metal screen: Lead					/ /
Heavy metal screen: Arsenic					/ /
Heavy metal screen: Mercury					/ /
Drug screen: Peak acetaminophen concentration					/ /
Urine toxicology (please provide details of any positive tox results)					/ /

Section 5: Laboratory results / Toxicology / Investigations NOTE: Please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed. Investigations Performed If yes, please summarise Date of test findings: Radiology: Yes□ No□ Liver biopsy* (summarise histopathology report, including whether damage starting at portal tracts or diffuse) Yes □ No □ List immunohistochemistry stains performed* (adenovirus/CMV/EBV etc) *Not be considered a recommended / mandatory test, based on clinical need. Section 6: Case medical and health history Did the case have COVID-19? Yes □ Suspected □ Unknown □ No □ Was it confirmed by a test (most recent episode)? Yes □ [PCR □; Rapid antigen test □] ΝоП Date of onset (most recent episode) (dd/mm/yyyy): Please summarize any other previous illnesses requiring treatment/care in the 5 months prior to diagnosis: Hospitalisation Primary Over the Illness type (e.g., Date of gastrointestinal illness. required onset/days **Symptoms** counter or injury) (yes/no) to prescribed medication resolution taken

Please describe any other medication the case has been prescribed in the 5 months prior to diagnosis	
Does the case have any underlying medical condition? Including liver related/metabolic/autoimmune/ischaemic	Yes□ No□
If yes, details: (diagnosis, date of diagnosis, medication)	/ /
Is the case immunosuppressed?	Yes □ No □
If yes, details: [condition (include if primary, secondary, medication related], date of diagnosis, medication)	/ /
Does or has the case take(n) any supplements or medicines acquired, over the counter, purchased over the internet or accessed by any other methods? (Including herbal, alternative medicines, vitamins, or other supplements); specifically, prompt acetaminophen/anti-inflammatory drugs (e.g., aspirin, ibuprofen)/anticonvulsants in the 5 months prior to diagnosis?	Yes No
If yes, details: (product, dose and frequency, where purchased)	/ /
Has the patient received any vaccine in the 5 months prior to diagnosis?	Yes□ No□
If yes, details: (type, date of administration)	/ /
Has the patient received a COVID-19 vaccine?	Yes□ No□ Date:
Does the patient have autoimmune hepatitis? Yes □ No □ Unknown □	If yes, details:

Does the patient have HLH	If yes, details:
(Hemophagocytic Lymphohistiocytosis)?	
Yes□ No□ Unknown□	

Section 7: Interviewee details (case or parent/guardian)			
Interviewee name:		Relationship to the case (if not interviewing the case):	
Cell phone:		Email address:	

PART B: EXPOSURE INFORMATION

Section 8: Exposure to	Section 8: Exposure to ill contacts		
Does the case regularly	Does the case regularly go to daycare or school? Yes □ No □		
Provide recent details of illnesses or infections among close contacts ³ , including group settings (e.g., outbreak in classroom), in the 5 months prior to diagnosis of the case if known:			
Nature of contact (household, daycare, etc.)	Illness type (e.g., Gastro, COVID-19)	Date of symptom onset or test result (if asymptomatic)	
		/ /	
		/ /	
		/ /	
		/ /	

³ Close contacts are defined as having cared for, lived with, spent significant time within close quarters (e.g., coworker, daycare) or had direct contact with respiratory secretions and other body fluids (e.g., feces) in the 5 months prior to case onset.

Have any close contacts been jaundiced or had a	Yes□ No□
similar condition (gastrointestinal symptoms, etc.) in the	
5 months prior to diagnosis of the case?	

Section 9: Exposure to animals	
Has the case had contact with animals? Yes \square No \square	
If yes, specify type of animal (e.g., dog, cat, guinea pig, livestock, backyard poultry, petting zoo, etc.):	

Section 10: Travel History	
In the 5 months prior to diagnosis of acute hepatitis, has the case had any day trips, travel and/or overnight visits to other households or locations? Please ensure to include any travel/trips to another province within Canada and outside Canada.	Yes □ No □ If yes, specify province, territory (circle) or country: BC AB SK MB ON QC NB NS PE NL YK NT NU
Has any household contact travelled or has the case been in close contact with visitors in the 5 months prior to diagnosis? Please ensure to include any travel to or visitors from another province within Canada and outside Canada.	Yes □ No □ If yes, specify province, territory (circle) or country: BC AB SK MB ON QC NB NS PE NL YK NT NU

Are there any other remarkable events, interactions, or experiences in the 5 months prior to diagnosis that have not been discussed so far that might be important or that you suspect may have caused or contributed to the illness? This may include parties or	Section 11: Any other information	
functions.	remarkable events, interactions, or experiences in the 5 months prior to diagnosis that have not been discussed so far that might be important or that you suspect may have caused or contributed to the illness? This may include parties or	

END OF QUESTIONNAIRE